Gene: VEGFC
Official Full Name: vascular endothelial growth factor Cprovided by HGNC
Gene Summary: The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. The encoded protein promotes angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. The proprotein is further cleaved into a fully processed form that can bind and activate VEGFR-2 and VEGFR-3 receptors. [provided by RefSeq, Apr 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO10442 | VEGFC Knockout cell line (HeLa) | Human | VEGFC | 1:3~1:6 | Negative | Online Inquiry |
KO10443 | VEGFC Knockout cell line (HEK293) | Human | VEGFC | 1:3~1:6 | Negative | Online Inquiry |
KO10444 | VEGFC Knockout cell line (A549) | Human | VEGFC | 1:3~1:4 | Negative | Online Inquiry |
VEGFC Gene Knockout Cell Lines are specialized cellular models designed to facilitate the study of vascular endothelial growth factor C (VEGFC), a critical protein in the regulation of angiogenesis and lymphangiogenesis. These cell lines have been genetically modified to disrupt the expression of the VEGFC gene, providing researchers with a powerful tool to investigate the downstream biological effects and pathways influenced by this growth factor.
The primary function of these knockout cell lines is to elucidate the role of VEGFC in various physiological and pathological processes. Through the mechanism of gene knockout, researchers can assess changes in cell behavior, including proliferation, migration, and overall cellular signaling pathways, under conditions where VEGFC is absent. This not only enhances the understanding of how VEGFC contributes to tumor growth and metastasis but also sheds light on its implications in diseases such as lymphedema and chronic inflammation.
Scientifically, VEGFC Gene Knockout Cell Lines are invaluable in both research and clinical settings. They offer insights into angiogenic processes and enable the development of targeted therapeutic interventions. By leveraging these cell lines, researchers can better explore potential drug candidates aimed at modulating VEGFC signaling, contributing to advancements in cancer therapy and regenerative medicine.
One of the specific advantages of our VEGFC Gene Knockout Cell Lines is their validated genetic modification, which ensures high specificity and reproducibility in experimental outcomes. Compared to alternative models that may rely on pharmacological blocking of VEGFC, these knockout lines provide a more precise investigation of VEGFC's role due to the complete absence of the gene, allowing for clearer interpretation of results.
The value of these cell lines to researchers and clinicians lies in their ability to drive innovation in therapeutic approaches and enhance scientific understanding of disease mechanisms. By utilizing these cell lines, users can streamline their research processes and achieve more accurate and impactful results.
With extensive expertise in cellular biology and genetic engineering, our company is dedicated to providing high-quality biological products that empower the scientific community to push the boundaries of research. Our VEGFC Gene Knockout Cell Lines represent our commitment to advancing knowledge and discovery in the field of biomedical research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.